Over the past half-century, a growing belief among women and their physicians
held that "replacing" the estrogen lost at menopause would prevent many of
the manifestations of aging, including coronary heart disease (CHD), osteoporotic
fractures, and a decline in cognitive and sexual function. This attractive
and plausible view led to widespread use of hormone therapy after menopause
in the era before randomized trials with disease end points were required
for proving the effects of new drugs. Clinicians were drawn in by other accumulating
lines of evidence for CHD benefit that were consistently favorable: observational
studies showed less heart disease among women taking estrogen,1 pathophysiologic
mechanisms provided biological plausibility,2 and
clinical trials revealed improvements in blood lipid levels and other surrogate
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 99
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.